文献速递消化系统肿瘤

30年经验——腹腔热灌注化疗治疗胃癌的随机与高质量非随机研究的Meta分析

The 30-year experience-A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer.
PubMed 文献 · Eur J Cancer · 2017-04-26

该研究系统检索1985年至2016年Medline和Embase数据库,纳入11项随机对照试验和21项非随机对照试验共2520例晚期胃癌患者,采用随机效应网络Meta分析评估腹腔热灌注化疗(HIPEC)的疗效。结果表明,无腹膜癌患者接受HIPEC可改善3年或5年总生存(RR=0.82,P=0.01);有腹膜癌患者3年总生存无差异(RR=0.99,P=0.85),但中位生存延长4个月(WMD=4.04,P<0.001);HIPEC组并发症风险显著增高(有腹膜癌RR=2.15,无腹膜癌RR=2.17,均P<0.01)。

要点

  • 无腹膜癌患者接受HIPEC可改善3年或5年总生存(RR=0.82,P=0.01)。
  • 有腹膜癌患者HIPEC组3年总生存无差异(RR=0.99,P=0.85),中位生存延长4个月(WMD=4.04,P<0.001)。
  • HIPEC组并发症风险显著增高(有腹膜癌RR=2.15,无腹膜癌RR=2.17,均P<0.01),与全身药物毒性相关。

核心结论

  • 研究表明HIPEC作为预防性策略具有生存优势,并提示疾病负荷限于细胞学阳性和有限淋巴结受累的患者可能从HIPEC中获益最多。
  • 对于广泛腹膜癌患者,细胞减灭术的完整性是生存的关键预后因素。
  • 未来随机对照试验应更好地定义患者选择标准。

研究设计与样本

  • 随机效应网络Meta分析,纳入11项随机对照试验和21项非随机对照试验,共2520例晚期胃癌患者。
  • 检索Medline和Embase数据库1985年1月1日至2016年6月1日的文献。
  • 纳入比较HIPEC与标准肿瘤治疗的随机对照试验和高质量非随机对照试验(采用非随机研究方法学指数 validated tool 筛选)。

主要发现

  • 无腹膜癌患者中,HIPEC组与对照组3年或5年总生存率比较有利于HIPEC组(RR=0.82,P=0.01)。
  • 有腹膜癌患者中,3年总生存无差异(RR=0.99,P=0.85),但HIPEC组中位生存延长4个月(WMD=4.04,P<0.001)。
  • HIPEC组并发症风险显著增高:有腹膜癌患者RR=2.15(P<0.01),无腹膜癌患者RR=2.17(P<0.01),风险增加与全身药物毒性相关。
  • 两组吻合口漏发生率相似。

关键数值与推荐

  • 无腹膜癌患者HIPEC组与对照组3年或5年总生存率比较:RR=0.82,P=0.01。
  • 有腹膜癌患者3年总生存:RR=0.99,P=0.85;中位生存延长4个月:WMD=4.04,P<0.001。
  • 有腹膜癌患者并发症风险:RR=2.15,P<0.01;无腹膜癌患者:RR=2.17,P<0.01。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Hyperthermic intraperitoneal chemotherapy (HIPEC) has been used within various multimodality strategies for the prevention and treatment of gastric cancer peritoneal carcinomatosis. OBJECTIVE: To systematically evaluate the role of HIPEC in gastric cancer and clarify its effectiveness at different stages of peritoneal disease progression. DATA SOURCES: Medline and Embase databases between January 1, 1985 and June 1, 2016. STUDY SELECTION: Randomised control trials and high-quality non-randomised control trials selected on a validated tool (methodological index for non-randomised studies) comparing HIPEC and standard oncological management for the treatment of advanced stage gastric cancer with and without peritoneal carcinomatosis were considered. DATA EXTRACTION AND SYNTHESIS: A random-effects network meta-analysis. MAIN OUTCOMES AND MEASURES: The primary outcomes were overall survival and disease recurrence. Secondary outcomes were overall complications, type of complications, and sites of recurrence. RESULTS: A total of 11 RCTs and 21 non-randomised control trials (2520 patients) were included. For patients without the presence of peritoneal carcinomatosis (PC), the overall survival rates between the HIPEC and control groups at 3 or 5 years resulted in favour of the HIPEC group (risk ratio [RR] = 0.82, P = 0.01). No difference in the 3-year overall survival (RR = 0.99, P = 0.85) in but a prolonged median survival of 4 months in favour of the HIPEC group (WMD = 4.04, P < 0.001) was seen in patients with PC. HIPEC was associated with significantly higher risk of complications for both patients with PC (RR = 2.15, P < 0.01) and without (RR = 2.17, P < 0.01). This increased risk in the HIPEC group was related to systemic drugs toxicity. Anastomotic leakage rates were found to be similar between groups. CONCLUSIONS: Our study demonstrates a survival advantage of the use of HIPEC as a prophylactic strategy and suggests that patients whose disease burden is limited to positive cytology and limited nodal involvement may benefit the most from HIPEC. For patients with extensive carcinomatosis, the completeness of cytoreductive surgery is a critical prognostic factor for survival. Future RCTs should better define patient selection criteria.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Desiderio J, Chao J, Melstrom L, et al. The 30-year experience-A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. Eur J Cancer. 2017. PMID: 28456089. doi:10.1016/j.ejca.2017.03.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。